A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
A Phase 1, Open-label, Multi-part Study to Evaluate Pharmacokinetics, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 Following Intravenous and Subcutaneous Administrations in Healthy Adults and Multiple Doses of BMS-986446 in Participants With Early Alzheimer's Disease.
The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: First line of the email MUST contain NCT # and Site #.
연구 연락처 백업
- 이름: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- 전화번호: 855-907-3286
- 이메일: Clinical.Trials@bms.com
연구 장소
-
-
California
-
Anaheim, California, 미국, 92801
- 모병
- CenExel ACT (Formerly Anaheim Clinical Trials; LLC)
-
연락하다:
- Amina Haggag, Site 0001
- 전화번호: 714-774-7777
-
-
Florida
-
Bradenton, Florida, 미국, 34205
- 아직 모집하지 않음
- Local Institution - 0003
-
연락하다:
- Site 0003
-
Daytona Beach, Florida, 미국, 32117
- 아직 모집하지 않음
- Local Institution - 0005
-
연락하다:
- Site 0005
-
Naples, Florida, 미국, 34105
- 아직 모집하지 않음
- Local Institution - 0007
-
연락하다:
- Site 0007
-
The Villages, Florida, 미국, 32162
- 아직 모집하지 않음
- Local Institution - 0006
-
연락하다:
- Site 0006
-
-
Georgia
-
Decatur, Georgia, 미국, 30030
- 아직 모집하지 않음
- Local Institution - 0004
-
연락하다:
- Site 0004
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria
- Participants must have a BMI of 18.0 to 35.0 kg/m2.
- For Parts A and B: Participants must be healthy as determined by medical history, Physical Examination (PE), neurological examination, vital signs, 12-lead ECG, Columbia Suicide-Severity Rating Scale (C-SSRS), and clinical laboratory evaluations.
- For Part C: Participants must meet diagnostic criteria for MCI or mild AD dementia, consistent with the National Institute on Aging and the Alzheimer's Association (NIA-AA) diagnostic criteria.
- For Part C: Participants must have an Mini Mental State Examination (MMSE) score of ≥ 20 to 28 (inclusive).
- For Part C: Participants must have evidence of positive plasma pTau217.
Exclusion Criteria
- For Parts A and B: Participants must not have a general history of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, immune-mediated disorder, hematological, ongoing allergic disorder requiring treatment, metabolic disorder, cancer, or cirrhosis.
- For Parts A and B: Participants must not have donated or lost 500 mL blood or more within 60 days prior to study intervention administration.
- For Part C: Participants must not have a neurological condition that in the opinion of the investigator may be contributing to cognitive impairment aside from the AD diagnosis, including but not limited to: Parkinson's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, long COVID, or baseline intellectual disability.
- For Part C: Participants must not have any current primary psychiatric diagnosis (eg, major depression, schizoaffective disorder or bipolar disorder) other than AD or symptoms (eg, hallucination or delusions).
- Other protocol-defined Inclusion/Exclusion criteria apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Panel A1: BMS986446
|
Specified dose on specified days
다른 이름들:
|
|
실험적: Panel A2: BMS986446
|
Specified dose on specified days
다른 이름들:
|
|
실험적: Panel A3: BMS986446
|
Specified dose on specified days
다른 이름들:
|
|
실험적: Panel B1: BMS986446
|
Specified dose on specified days
다른 이름들:
|
|
실험적: Panel B2: BMS986446
|
Specified dose on specified days
다른 이름들:
|
|
실험적: Panel C1: BMS986446
|
Specified dose on specified days
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Absolute bioavailability estimated from geometric mean ratio (GMR) of area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986446 after subcutaneous (SC) infusion
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Absolute bioavailability estimated from GMR of AUC(INF) of BMS-986446 after intravenous (IV) infusion
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Maximum observed concentration (Cmax)
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Time of maximum observed concentration (Tmax)
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Area under the serum concentration-time curve from time zero to 672 hours (AUC(0-672))
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
AUC(INF)
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Half-life (T-HALF)
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Apparent total body clearance in SC administration (CLT/F)
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Total body clearance in IV infusion (CLT)
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Apparent volume of distribution of terminal phase in SC administration (Vz/F)
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Volume of distribution of terminal phase (VZ)
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Adverse events (AEs)
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
Serious adverse events (SAEs)
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
AEs reported as related to BMS-986446
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
Incidence of anti-drug antibody (ADA)
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B1 vs Panel A3 for Cmax
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B1 vs Panel A3 for area under the concentration-time curve (AUC)
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B2 vs Panel A3 for Cmax
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B2 vs Panel A3 for AUC
기간: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
Local tolerance evaluation
기간: Up to approximately 5 months
|
This evaluation will assess pain, itching, burning, pressure, and soreness/tenderness (using a Numeric Rating Scale) at the injection site location. |
Up to approximately 5 months
|
|
Cmax
기간: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
Tmax
기간: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
AUC(0-T)
기간: Up to approximately 5 months
|
Panel B1, Panel B2 |
Up to approximately 5 months
|
|
AUC(0-672)
기간: Up to approximately 5 months
|
Panel B1, Panel B2 |
Up to approximately 5 months
|
|
AUC(INF)
기간: Up to approximately 5 months
|
Panel B1, Panel B2 |
Up to approximately 5 months
|
|
T-HALF
기간: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
CLT/F
기간: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
Vz/F
기간: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
Trough observed plasma concentration (Ctrough)
기간: Up to approximately 5 months
|
Panel C1 |
Up to approximately 5 months
|
|
Concentration at the end of a dosing interval (Ctau)
기간: Up to approximately 5 months
|
Panel C1 |
Up to approximately 5 months
|
|
Area under the concentration-time curve within a dosing interval (AUC(TAU))
기간: Up to approximately 5 months
|
Panel C1 |
Up to approximately 5 months
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Bristol-Myers Squibb, Bristol-Myers Squibb
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- CN008-0028
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD 공유 기간
See Plan Description
IPD 공유 액세스 기준
See Plan Description
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .